Login Register Cart 0
Perspective

Abrocitinib:首个全球批准用于治疗特应性皮炎的选择性Janus激酶-1抑制剂

卷 30, 期 38, 2023

发表于: 06 March, 2023

页: [4278 - 4282] 页: 5

弟呕挨: 10.2174/0929867330666230216123419

Open Access Journals Promotions 2
conference banner
摘要

特应性皮炎是指表皮增生、皮肤屏障功能障碍和免疫细胞异常激活。Janus kinase (JAK)是一个细胞质非受体酪氨酸激酶家族，由四个成员组成，如JAK1、JAK2、JAK3和TYK2。JAK信号通路在包括特应性皮炎在内的多种自身免疫性疾病和炎症性疾病中发挥关键作用。Abrocitinib是一种口服生物可利用的选择性JAK1抑制剂，于2022年1月获批用于治疗特应性皮炎。综述了阿布昔替尼的化学结构、物理性质、合成方法、作用机制和药动学特征。

关键词: 阿布替尼，特应性皮炎，Janus激酶，酪氨酸激酶，自身免疫，炎症性疾病。

« Previous Next »
[1]
Mastraftsi, S.; Vrioni, G.; Bakakis, M.; Nicolaidou, E.; Rigopoulos, D.; Stratigos, A.J.; Gregoriou, S. Atopic dermatitis: Striving for reliable biomarkers. J. Clin. Med., 2022, 11(16), 4639.
[http://dx.doi.org/10.3390/jcm11164639] [PMID: 36012878]
[2]
Ständer, S. Atopic dermatitis. N. Engl. J. Med., 2021, 384(12), 1136-1143.
[http://dx.doi.org/10.1056/NEJMra2023911] [PMID: 33761208]
[3]
Ayen-Rodríguez, A.; Pereyra-Rodríguez, J.J.; Navarro-Triviño, F.J.; Alcantara-Luna, S.; Domínguez-Cruz, J.; Galán-Gutiérrez, M.; Vilar-Palomo, S.; Armario-Hita, J.C.; Ruiz-Villaverde, R. Long-term effectiveness and safety of biologic and small molecule drugs for moderate to severe atopic dermatitis: A systematic review. Life, 2022, 12(8), 1159.
[http://dx.doi.org/10.3390/life12081159] [PMID: 36013338]
[4]
Reich, K.; Thyssen, J.P.; Blauvelt, A.; Eyerich, K.; Soong, W.; Rice, Z.P.; Hong, H.C.; Katoh, N.; Valenzuela, F.; DiBonaventura, M.; Bratt, T.A.; Zhang, F.; Clibborn, C.; Rojo, R.; Valdez, H.; Kerkmann, U. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A randomised, double-blind, multicentre phase 3 trial. Lancet, 2022, 400(10348), 273-282.
[http://dx.doi.org/10.1016/S0140-6736(22)01199-0] [PMID: 35871814]
[5]
Gooderham, M.J.; Forman, S.B.; Bissonnette, R.; Beebe, J.S.; Zhang, W.; Banfield, C.; Zhu, L.; Papacharalambous, J.; Vincent, M.S.; Peeva, E. Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis. JAMA Dermatol., 2019, 155(12), 1371-1379.
[http://dx.doi.org/10.1001/jamadermatol.2019.2855] [PMID: 31577341]
[6]
Silverberg, J.I.; Simpson, E.L.; Thyssen, J.P.; Gooderham, M.; Chan, G.; Feeney, C.; Biswas, P.; Valdez, H.; DiBonaventura, M.; Nduaka, C.; Rojo, R. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis. JAMA Dermatol., 2020, 156(8), 863-873.
[http://dx.doi.org/10.1001/jamadermatol.2020.1406] [PMID: 32492087]
[7]
Le, M.; Berman-Rosa, M.; Ghazawi, F.M.; Bourcier, M.; Fiorillo, L.; Gooderham, M.; Guenther, L.; Hanna, S.; Hong, H.C.H.; Landells, I.; Lansang, P.; Marcoux, D.; Wiseman, M.C.; Yeung, J.; Lynde, C.; Litvinov, I.V. Systematic review on the efficacy and safety of oral janus kinase inhibitors for the treatment of atopic dermatitis. Front. Med., 2021, 8, 682547.
[http://dx.doi.org/10.3389/fmed.2021.682547] [PMID: 34540860]
[8]
Bieber, T.; Simpson, E.L.; Silverberg, J.I.; Thaçi, D.; Paul, C.; Pink, A.E.; Kataoka, Y.; Chu, C.Y.; DiBonaventura, M.; Rojo, R.; Antinew, J.; Ionita, I.; Sinclair, R.; Forman, S.; Zdybski, J.; Biswas, P.; Malhotra, B.; Zhang, F.; Valdez, H. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N. Engl. J. Med., 2021, 384(12), 1101-1112.
[http://dx.doi.org/10.1056/NEJMoa2019380] [PMID: 33761207]
[9]
Crowley, E.L.; Nezamololama, N.; Papp, K.; Gooderham, M.J. Abrocitinib for the treatment of atopic dermatitis. Expert Rev. Clin. Immunol., 2020, 16(10), 955-962.
[http://dx.doi.org/10.1080/1744666X.2021.1828068] [PMID: 32969750]
[10]
Simpson, E.L.; Sinclair, R.; Forman, S.; Wollenberg, A.; Aschoff, R.; Cork, M.; Bieber, T.; Thyssen, J.P.; Yosipovitch, G.; Flohr, C.; Magnolo, N.; Maari, C.; Feeney, C.; Biswas, P.; Tatulych, S.; Valdez, H.; Rojo, R. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet, 2020, 396(10246), 255-266.
[http://dx.doi.org/10.1016/S0140-6736(20)30732-7] [PMID: 32711801]
[11]
Vazquez, M.L.; Kaila, N.; Strohbach, J.W.; Trzupek, J.D.; Brown, M.F.; Flanagan, M.E.; Mitton-Fry, M.J.; Johnson, T.A.; TenBrink, R.E.; Arnold, E.P.; Basak, A.; Heasley, S.E.; Kwon, S.; Langille, J.; Parikh, M.D.; Griffin, S.H.; Casavant, J.M.; Duclos, B.A.; Fenwick, A.E.; Harris, T.M.; Han, S.; Caspers, N.; Dowty, M.E.; Yang, X.; Banker, M.E.; Hegen, M.; Symanowicz, P.T.; Li, L.; Wang, L.; Lin, T.H.; Jussif, J.; Clark, J.D.; Telliez, J.B.; Robinson, R.P.; Unwalla, R. Identification of N-cis -3-[Methyl(7 H -pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutylpropane-1-sulfonamide (PF-04965842): A selective JAK1 clinical candidate for the treatment of autoimmune diseases. J. Med. Chem., 2018, 61(3), 1130-1152.
[http://dx.doi.org/10.1021/acs.jmedchem.7b01598] [PMID: 29298069]
[12]
Connor, C.G.; DeForest, J.C.; Dietrich, P.; Do, N.M.; Doyle, K.M.; Eisenbeis, S.; Greenberg, E.; Griffin, S.H.; Jones, B.P.; Jones, K.N.; Karmilowicz, M.; Kumar, R.; Lewis, C.A.; McInturff, E.L.; McWilliams, J.C.; Mehta, R.; Nguyen, B.D.; Rane, A.M.; Samas, B.; Sitter, B.J.; Ward, H.W.; Webster, M.E. Development of a nitrene-type rearrangement for the commercial route of the JAK1 inhibitor abrocitinib. Org. Process Res. Dev., 2021, 25(3), 608-615.
[http://dx.doi.org/10.1021/acs.oprd.0c00366]
[13]
Bauman, J.N.; Doran, A.C.; King-Ahmad, A.; Sharma, R.; Walker, G.S.; Lin, J.; Lin, T.H.; Telliez, J.B.; Tripathy, S.; Goosen, T.C.; Banfield, C.; Malhotra, B.K.; Dowty, M.E. The pharmacokinetics, metabolism, and clearance mechanisms of abrocitinib, a selective janus kinase inhibitor, in humans. Drug Metab. Dispos., 2022, 50(8), 1106-1118.
[http://dx.doi.org/10.1124/dmd.122.000829] [PMID: 35701182]
[14]
Ortiz de M.P.R.. Hydrocarbon hydroxylation by cytochrome P450 enzymes. Chem. Rev., 2010, 110(2), 932-948.
[http://dx.doi.org/10.1021/cr9002193] [PMID: 19769330]
[15]
Nogueira, M.; Torres, T. Janus kinase inhibitors for the treatment of atopic dermatitis: Focus on abrocitinib, baricitinib, and upadacitinib. Dermatol. Pract. Concept., 2021, 11(4), e2021145.
[http://dx.doi.org/10.5826/dpc.1104a145] [PMID: 35024237]
[16]
He, H.; Guttman-Yassky, E. JAK inhibitors for atopic dermatitis: An update. Am. J. Clin. Dermatol., 2019, 20(2), 181-192.
[http://dx.doi.org/10.1007/s40257-018-0413-2] [PMID: 30536048]
[17]
Peeva, E.; Hodge, M.R.; Kieras, E.; Vazquez, M.L.; Goteti, K.; Tarabar, S.G.; Alvey, C.W.; Banfield, C. Evaluation of a janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study. Br. J. Clin. Pharmacol., 2018, 84(8), 1776-1788.
[http://dx.doi.org/10.1111/bcp.13612] [PMID: 29672897]
[18]
Lee, K.P.; Plante, J.; Korte, J.E.; Elston, D.M. Oral Janus kinase inhibitors in the treatment of atopic dermatitis: A systematic review and meta‐analysis. Skin Health Dis., 2022, 2022, e133.
[http://dx.doi.org/10.1002/ski2.133]
[19]
Cartron, A.M.; Nguyen, T.H.; Roh, Y.S.; Kwatra, M.M.; Kwatra, S.G. Janus kinase inhibitors for atopic dermatitis: A promising treatment modality. Clin. Exp. Dermatol., 2021, 46(5), 820-824.
[http://dx.doi.org/10.1111/ced.14567] [PMID: 33484582]

Rights & Permissions Print Cite
Article Metrics
81
4
Wayfinder Image
Open Access Journals Promotions
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy